Associate Director HEOR Hematology (a)

Your main tasks include:

• Leading HEOR support for three hematology assets in Europe, including two anticipated launches in 2027, with a strong focus on EU Joint Clinical Assessment (JCA) preparedness.
• Coordinating cross-functional JCA planning and execution across Market Access, Clinical Development, Regulatory Affairs, Safety, Medical Affairs, Biostatistics, and Global teams.
• Supporting the development and implementation of evidence strategies to address JCA, HTA, reimbursement, and broader market access requirements.
• Identifying evidence gaps and translating JCA/PICO requirements into evidence-generation plans and priorities.
• Supporting JCA PICO assessment and planning, including evaluation of target populations, comparators, outcomes, and evidence availability.
• Leading the coordination and review of externally generated evidence packages, including indirect treatment comparisons, real-world evidence studies, and other HEOR analyses.
• Managing external HEOR and evidence-generation vendors, ensuring delivery of high-quality outputs aligned with JCA timelines and business needs.
• Reviewing study protocols, analysis plans, reports, and evidence deliverables to ensure methodological appropriateness and strategic relevance.
• Facilitating alignment among internal stakeholders on evidence-generation priorities, assumptions, and interpretation of results.
• Supporting the communication of evidence and key findings to internal stakeholders to inform HTA and access strategies.
• Contributing to JCA readiness activities for upcoming hematology launches and supporting broader portfolio priorities as needed.

• Master's degree or PhD in Health Economics, Outcomes Research, Epidemiology, Public Health, Statistics or a related discipline.
• 5+ years of relevant experience in HEOR, HTA, RWE or comparative effectiveness research, preferably within the pharmaceutical industry or consulting.
• Good understanding of European HTA and evidence requirements; knowledge or experience with the EU HTA Regulation and JCA would be a strong asset.
• Experience with comparative effectiveness methods such as ITC/NMA and population-adjusted approaches (e.g. MAIC/STC) would be highly desirable.
• Experience designing, managing and critically reviewing HEOR studies and working with external research vendors.
• Knowledge or experience in hematology/oncology would be an asset.
• Strong analytical and critical-thinking skills, with the ability to translate evidence gaps into practical research activities.
• Ability to work effectively in a cross-functional matrix environment and manage multiple projects and changing priorities.
• Excellent written and verbal communication skills in English.
• Highly organized, proactive and able to work independently in a fast-paced environment.

• Working on high-impact HEOR projects supporting innovative hematology therapies across Europe.
• Gaining hands-on experience in HTA, EU JCA, real-world evidence, and market access strategy.
• Joining a collaborative international team in Basel on a flexible 6-9 month assignment with extension option.
• Choose from 80-100% work pensum, remote work from Switzerland possible.